Logo

InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

Share this
InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

Shots:

  • InveniAI is eligible to receive up to $200M/ program as up front- development- and commercial milestones along with royalties
  • The collaboration integrates InveniAI's AI platform AlphaMeld to identify- evaluate- optimize novel targets with Shionogi's expertise in developing and commercializing therapeutic modalities
  • Shionogi will synthesize targets identified by InveniAI for certain strategic diseases and will be responsible for developing- manufacturing- and commercializing the candidates

  Ref: GlobeNewswire | Image: Pharma Boardroom

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions